| Authors: |
Böttcher M; Clinical Pharmacology, Bayer AG, Wuppertal, Germany., Düngen HD; Department of Internal Medicine, Cardiology, Charité-Universitaetsmedizin Berlin, Berlin, Germany., Corcea V; Department of Cardiac Surgery, PMSI Clinical Republican Hospital 'T. Mosneaga', Chisinau, Republic of Moldova., Donath F; SocraTec R&D GmbH, Erfurt, Germany., Fuhr R; Early Phase Clinical Unit, Parexel, Berlin, Germany., Gal P; Centre for Human Drug Research, Leiden, The Netherlands.; Clinical Pharmacology and Toxicology Department, Leiden University Medical Center, Leiden, The Netherlands., Mikus G; Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany., Trenk D; Department University Heart Center Campus Bad Krozingen, Clinics of Cardiology and Angiology-Clinical Pharmacology, University Medical Center Freiburg, Freiburg, Germany., Coenen M; Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany., Pires PV; Research and Development, Bayer AG, Wuppertal, Germany., Maschke C; Study Management, Bayer AG, Wuppertal, Germany., Aliprantis AO; Translational Medicine, Merck & Co., Inc., Rahway, New Jersey, USA.; Pioneering Medicines, Flagship Pioneering, Boston, Massachusetts, USA., Besche N; Chrestos Concept GmbH & Co. KG, Essen, Germany., Becker C; Clinical Pharmacology, Bayer AG, Wuppertal, Germany. corina.becker@bayer.com. |
